ADC Reports EMA’s Validation of MAA for Zynlonta to Treat R/R Diffuse Large B-Cell Lymphoma Published: Oct 29, 2021 | Tags: ADC, EMA, MAA, Zynlonta, R/R Diffuse Large B-Cell Lymphoma […]readmore
Tags : Impact
Shots: The company will initiate the P-I/II dose-escalation & expansion study to evaluate the safety, PK & anti-tumor activities of IMP9064 as monothx. & in combination with Senaparib in patients […]readmore
Introduction: “Over-prescription” is defined as the action of prescribing a drug or treatment in greater amount or on more occasions than necessary. Overprescribing, in general in health care, has been […]readmore
The concept of telemedicine has evolved in recent years. As people are demanding easier ways to avail of medical treatment and diagnosis, there have been several advances in telemedicine. Telemedicine […]readmore
Shots: The two companies will co-develop and conduct clinical trials for senaparib across multiple cancer indications in China. Junshi to invest $43.4M in cash, representing 50% of the JV while […]readmore
Medical Affairs is a critical scientific bridge between Healthcare companies and their internal & external stakeholders. It plays a leadership role in implementing cutting-edge medical, scientific, and patient-centered insights & […]readmore
COVID-19 has casted the healthcare community into disarray. Healthcare providers are stressed as the disease has affected more people than the production capacity of healthcare companies to manufacture ventilators, personal […]readmore
Shots: The online survey assesses 76 patients from the Platelet Disorder Support Association that has been diagnosed with ITP, prior treated with at least one therapy. The 30-45-min online survey […]readmore